ST2 as a Marker for Risk of Therapy-Resistant Graft-versus-Host Disease and Death.

The article presents a study which focuses on the consideration of the association of suppression of tumorgenecity 2 (ST2) with the resistance of graft-versus-host (GVHD) therapy and death. The measurement of the lead biomarker was made at the beginning of the treatment for GVHD in plasma. Results show that the risk stratification for treatment-resistant GVHD was improved by the measurement of ST2 levels at the initiation of therapy for the disease.